Corporate Profile
Founded in 1992, Conceptus®, Inc. is dedicated to the revolutionary design, development, and marketing of innovative solutions to advance women's health. We developed the market leading Essure® procedure, the first-ever non-surgical permanent birth control method. After a decade on the market, Essure remains the most effective form of permanent birth control* available worldwide. We are committed to making Essure the standard of care for permanent birth control, and we intend to provide additional women's health solutions for both patients and physicians.
*based on four years of clinical study data
Shareholder information
Exchange:
Conceptus, Inc.'s common stock trades on The NASDAQ Global Select MarketSM under the symbol CPTS.
Transfer agent:
BNY Mellon Shareowner Services
P.O. Box 358015
Pittsburgh, PA 15252-8015
(877) 258-2911 (phone)
www.bnymellon.com/shareowner/equityaccess
View all » 
Recent Releases
Apr 29, 2013
Conceptus(R) Reports First Quarter Financial Results
Apr 29, 2013
Bayer HealthCare to Acquire Conceptus(R)